Managing high cholesterol is a serious challenge for children and teenagers with heterozygous familial hypercholesterolaemia. For these young patients, standard treatments like statins or ezetimibe often fail to bring their LDL levels down to safe targets. This makes it harder for them to manage their long-term heart health.
A review of clinical trials involving 451 children and adolescents found that adding PCSK9 inhibitors—specifically evolocumab, alirocumab, or inclisiran—to standard therapy works well. These medications led to a significant reduction in LDL cholesterol, cutting levels by about 35.44 percent compared to a placebo. This is a substantial drop for patients who were already struggling with their current treatment plans.
The study also looked at how these children tolerated the new treatments. The results showed no difference in safety or tolerability between those taking PCSK9 inhibitors and those on a placebo. While the findings are promising, it is important to note that the data comes from a limited number of trials with relatively short follow-up periods. Talk to a specialist to see if these options fit your child's specific needs.
